Kathrin Pahmeier

Kathrin Pahmeier

Auto-generated profile, based on publicly available information

Kathrin Pahmeier

Institute for Healthcare Management and Research, University of Duisburg-Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2019 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
SNSilke Neusser
Silke Neusser
BLBeate Lux
Beate Lux
CBCordula Barth
Cordula Barth
KPKathrin Pahmeier
Kathrin Pahmeier
KRKerstin Rhiem
Kerstin Rhiem
ANAnja Neumann
Anja Neumann
Objectives: Potential opportunities and challenges of predictive genetic risk classification of healthy persons are currently discussed. However, the budgetary impact of rising demand is uncertain. This project aims to evaluate budgetary consequences of predictive genetic risk classification for statutory health insurance in Germany. Methods: A Markov model was developed in the form of a cohort simulation. It analyzes a population of female relatives of hereditary breast cancer patients. Mutation carriers are offered intensified screening, women with a BRCA1 or BRCA2 mutation can decide on prophylactic mastectomy and/or ovarectomy. The model considers the following scenarios: (a) steady demand for predictive genetic testing, and (b) rising demand. Most input parameters are based on data of the German Consortium for Hereditary Breast and Ovarian Cancer. The model contains 49 health states, starts in 2015, and runs for 10 years. Prices were evaluated from the perspective of statutory health insurance. Results: Steady demand leads to an expenditure of €49.8 million during the 10-year period. Rising demands lead to additional expenses of €125.5 million. The model reveals the genetic analysis to be the main cost driver while cost savings in treatment costs of breast and ovarian cancer are indicated. Conclusions: The results contribute to close the knowledge gap concerning the budgetary consequences due to genetic risk classification. A rising demand leads to additional costs especially due to costs for genetic analysis. The model indicates budget shifts with cost savings due to breast and ovarian cancer treatment in the scenario of rising demands.

18 July 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
ASAndreas Stang
Andreas Stang
KSKatrin Schuldt
Katrin Schuldt
PTPietro Trocchi
Pietro Trocchi
SNSilke Neusser
Silke Neusser
CSChristian Speckemeier
Christian Speckemeier
MNMichael Nonnemacher
Michael Nonnemacher

11 July 2023 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
KPKathrin Pahmeier
Kathrin Pahmeier
CSChristian Speckemeier
Christian Speckemeier
SNSilke Neusser
Silke Neusser
JWJuergen Wasem
Juergen Wasem
JBJanine Biermann-Stallwitz
Janine Biermann-Stallwitz
Background and Objective In Germany, influenza vaccination is mainly advised for persons aged 60 years and over and individuals with health risks. Since 2021, an inactivated, quadrivalent high-dose influenza vaccine (IIV4-HD) has been recommended for persons aged 60 years and over. The aim of this study was to calculate the impact of vaccinating the German population aged 60 years and over with IIV4-HD compared to standard-dose influenza vaccines (IIV4-SD) with regard to health outcomes and costs. Methods An age-stratified deterministic compartment model was built to simulate the course of influenza infection for the German population in the season 2019/20. Probabilities for health outcomes and cost data were searched from the literature and were used to compare the influenza-related health and economic effects for different scenarios. Perspectives were those of the statutory health insurance and the society. Deterministic sensitivity analyses were conducted. Results From the statutory health insurance perspective, vaccinating the German population aged 60 years and over with IIV4-HD would have prevented 277,026 infections (− 1.1%) with an increase of overall direct costs of €224 million (+ 40.1%) compared with IIV4-SD. A separate analysis showed that increased vaccination of 75% (World Health Organization recommendation for older age groups) in persons aged 60 years and over using IIV4-SD only would prevent 1,289,648 infections (− 5.1%) and would save costs from a statutory health insurance perspective of €103 million (− 13.2%) compared with IIV4-HD at actual vaccination rates. Conclusions The modeling approach offers important insights into the epidemiological and budgetary impact of different vaccination scenarios. Achieving a higher vaccination coverage with IIV4-SD in persons aged 60 years and over would result in lower costs and fewer influenza infections compared with the scenario with IIV4-HD and actual vaccination rates.

20 August 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
KPKathrin Pahmeier
Kathrin Pahmeier
SNSilke Neusser
Silke Neusser
CHChristian Hamm
Christian Hamm
JKJohannes Kastner
Johannes Kastner
JWJochen Wöhrle
Jochen Wöhrle
FGFor the GABI-R Study Group
For the GABI-R Study Group
Background: Numerous studies have reported clinical endpoints following coronary revascularization using bioresorbable vascular scaffolds (BVS), while information about the impact on health-related quality of life is sparse. In this analysis of the German-Austrian ABSORB RegIstRy, the 2 year results concerning quality of life development in a large cohort of patients treated with BVS were reported. Methods: Data were collected at baseline as well as 30 days, 6 and 24 months after coronary revascularization using BVS. The EQ-5D score, EQ visual analogue scale (VAS) and Seattle Angina Questionnaire (SAQ) were determined for each time point. Patients were categorized according to the indication for coronary revascularization [acute coronary syndrome (ACS), stable angina pectoris (SAP), silent myocardial ischemia (SMI), or other]. Binary logistic regression analysis was performed to determine factors that predict above-average scores two years after implantation. Results: Data from 1317 patients in 88 centres were included. Reasons for revascularization were: ACS (n = 643), SAP (n = 443), SMI (n = 52), and other (n = 179). Mean EQ-5D was significantly increased after six months, while a value comparable to baseline was found two years after implantation. EQ VAS and four of five dimensions of SAQ were significantly improved over baseline at all follow-up surveys. Particularly strong improvements were seen in SAQ scores angina frequency and quality of life. Binary regressions showed different statistically significant predictors in the respective models. Conclusions: Following coronary revascularization with BVS strong decrease in self-reported angina frequency and increase of self-reported quality of life were observed with continuous improvements over two years of follow-up. Trial registration ClinicalTrials.gov Identifier: NCT02066623.

19 August 2025 in Gesundheitsökonomie & Qualitätsmanagement
Verified
Journal Article
Closed access
PDF file
KPKathrin Pahmeier
Kathrin Pahmeier
NLNico Lützel
Nico Lützel
GEGerhard Eschweiler
Gerhard Eschweiler
CTChristine Thomas
Christine Thomas
CAChristine A.F. von Arnim
Christine A.F. von Arnim
JBJanine Biermann-Stallwitz
Janine Biermann-Stallwitz
Zusammenfassung: Ziel war die Ermittlung der ökonomischen Bedeutung des postoperativen Delirs (POD) bei älteren Patienten nach Elektivoperationen aus Krankenhaus-Perspektive.Die Abrechnungsdaten von in der PAWEL-Studie rekrutierten Patienten (Alter ≧ 70 Jahre) aus zwei Studienzentren wurden analysiert. Die inkrementellen Kosten und Erlöse des PODs wurden mit einem generalisierten linearen Modell (GLM) geschätzt. Mit einer logistischen Regression wurde untersucht, ob das POD ein signifikanter Prädiktor einer Unterdeckung ist.Daten von 538 älteren Patienten bei elektiven größeren Operationen konnten analysiert werden (POD: 120, non-POD: 418). Die inkrementellen stationären Kosten je POD wurden im GLM auf 6870 € geschätzt, die Erlöse auf 5769 €. Das POD ist ein signifikanter Prädiktor einer Unterdeckung.Das Vorliegen eines PODs zeigt einen deutlichen, ökonomischen Effekt für die Krankenhäuser.